Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

NCT00935012 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00935012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00935012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
November 20, 2019
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

attr-cm, ttr-cm